Witnessing the stock’s movement on the chart, on Thursday, TransCode Therapeutics Inc (NASDAQ: RNAZ) set off with pace as it heaved 13.03% to $0.38, before settling in for the price of $0.34 at the close. Taking a more long-term approach, RNAZ posted a 52-week range of $0.22-$18.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was -28.81%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 98.22%. This publicly-traded company’s shares outstanding now amounts to $17.27 million, simultaneously with a float of $17.24 million. The organization now has a market capitalization sitting at $6.56 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4995, while the 200-day Moving Average is $0.6629.
TransCode Therapeutics Inc (RNAZ) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. TransCode Therapeutics Inc’s current insider ownership accounts for 0.16%, in contrast to 1.88% institutional ownership.
TransCode Therapeutics Inc (RNAZ) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
TransCode Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 98.22% and is forecasted to reach -0.46 in the upcoming year.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Let’s observe the current performance indicators for TransCode Therapeutics Inc (RNAZ). It’s Quick Ratio in the last reported quarter now stands at 1.58. The Stock has managed to achieve an average true range (ATR) of 0.06.
In the same vein, RNAZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -8.06, a figure that is expected to reach -0.16 in the next quarter, and analysts are predicting that it will be -0.46 at the market close of one year from today.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
Going through the that latest performance of [TransCode Therapeutics Inc, RNAZ]. Its last 5-days volume of 0.27 million was inferior to the volume of 1.24 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 22.99% While, its Average True Range was 0.0493.
Raw Stochastic average of TransCode Therapeutics Inc (RNAZ) in the period of the previous 100 days is set at 21.47%, which indicates a major fall in contrast to 28.69% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 93.21% that was lower than 213.98% volatility it exhibited in the past 100-days period.
